Market capitalization | $5.78m |
Enterprise Value | $400.00k |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | 0.44 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-7.39m |
Free Cash Flow (TTM) Free Cash Flow | $-7.11m |
Cash position | $5.38m |
As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.
1 Analyst has issued a forecast Phio Pharmaceuticals Corp.:
1 Analyst has issued a forecast Phio Pharmaceuticals Corp.:
Dec '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -0.04 -0.04 |
78%
78%
|
|
EBITDA | -7.35 -7.35 |
30%
30%
|
EBIT (Operating Income) EBIT | -7.39 -7.39 |
31%
31%
|
Net Profit | -7.15 -7.15 |
34%
34%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Phio Pharmaceuticals Corp. is a biotechnology company, which engages in the development of immuno-oncology therapeutics that addresses unmet medical needs. Its clinical product candidate includes RXI-109, an RNAi compound developed for the reduction of dermal scarring in planned surgeries. The company was founded on September 8, 2011 and is headquartered in Marlborough, MA.
Head office | United States |
CEO | Robert Bitterman |
Employees | 5 |
Founded | 2011 |
Website | www.phiopharma.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.